{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:06:22Z","timestamp":1777529182978,"version":"3.51.4"},"reference-count":32,"publisher":"SAGE Publications","issue":"4","license":[{"start":{"date-parts":[[2008,8,5]],"date-time":"2008-08-05T00:00:00Z","timestamp":1217894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cardiovasc Pharmacol Ther"],"published-print":{"date-parts":[[2008,12]]},"abstract":"<jats:p>\n                    Antimuscarinics, used commonly to treat overactive bladder, may differ in their potential to increase heart rate via effects on cardiac muscarinic M\n                    <jats:sub>2<\/jats:sub>\n                    receptors. This prospective, 3-way crossover, randomized, double-blind study assessed the heart rate effects of 7 days' exposure to a nonselective M\n                    <jats:sub>2<\/jats:sub>\n                    \/M\n                    <jats:sub>3<\/jats:sub>\n                    receptor blocker (tolterodine; 4 mg\/d), a highly selective M\n                    <jats:sub>3<\/jats:sub>\n                    receptor blocker (darifenacin; 15 mg\/d), and placebo in 162 healthy participants \u226550 years. Heart rate was measured by 24-hour Holter monitoring. Tolterodine significantly increased heart rate versus darifenacin and heart rate versus placebo, while darifenacin did not affect heart rate versus placebo. The proportion of participants with an increase in mean heart rate per 24 hours of \u22655 beats per minute was higher with tolterodine than with darifenacin (P = .0004) or with placebo (P = .0114) but did not differ between darifenacin and placebo. The results show that antimuscarinics exert differential effects on heart rate depending on their muscarinic receptor profile. This should be considered when selecting a treatment.\n                  <\/jats:p>","DOI":"10.1177\/1074248408325404","type":"journal-article","created":{"date-parts":[[2008,10,1]],"date-time":"2008-10-01T22:13:27Z","timestamp":1222899207000},"page":"241-251","source":"Crossref","is-referenced-by-count":57,"title":["Differential Pharmacological Effects of Antimuscarinic Drugs on Heart Rate: A Randomized, Placebo-controlled, Double-blind, Crossover Study With Tolterodine and Darifenacin in Healthy Participants \u226550 Years"],"prefix":"10.1177","volume":"13","author":[{"given":"Brian","family":"Olshansky","sequence":"first","affiliation":[{"name":"University of Iowa Hospitals, Iowa City, Iowa,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Ebinger","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Brum","sequence":"additional","affiliation":[{"name":"Procter and Gamble Pharmaceuticals Inc, Cincinnati, Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Egermark","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Viegas","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ludmyla","family":"Rekeda","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2008,8,5]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1002\/nau.10052"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(03)00622-7"},{"key":"atypb3","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1016\/S0022-3565(25)09628-4","volume":"273","author":"Wang P.","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2680.2001.00231.x"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.11.016"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0704781"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0706780"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.104.067140"},{"key":"atypb9","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1111\/j.1464-410X.2007.07100.x","volume":"100","author":"Andersson KE","year":"2007","journal-title":"BJU Int"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1124\/mol.59.5.1029"},{"key":"atypb11","volume-title":"Annual Meeting of the International Continence Society","author":"Napier C."},{"key":"atypb12","volume-title":"Annual Meeting of the International Continence Society","author":"Olshansky B."},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2007.04.079"},{"key":"atypb14","first-page":"1","volume":"43","author":"Lanza GA","year":"2006","journal-title":"Adv Cardiol"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-7061(04)00897-0"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9149(96)90077-6"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2006.09.019"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"atypb19","first-page":"406","volume":"20","author":"Stewart W.","year":"2001","journal-title":"Neurourol Urodyn"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a014868"},{"key":"atypb21","first-page":"653","volume":"26","author":"Andersson KE","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"atypb22","first-page":"654","volume":"26","author":"Andersson KE","year":"2007","journal-title":"Neurourol Urodyn"},{"key":"atypb23","doi-asserted-by":"publisher","DOI":"10.1253\/circj.71.A106"},{"key":"atypb24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.01.038"},{"key":"atypb25","doi-asserted-by":"publisher","DOI":"10.1096\/fj.03-0648fje"},{"key":"atypb26","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2004.01.008"},{"key":"atypb27","doi-asserted-by":"publisher","DOI":"10.1007\/s00192-005-1340-3"},{"key":"atypb28","first-page":"88S","volume":"105","author":"Romanzi LJ","year":"2005","journal-title":"Obstet Gynecol"},{"key":"atypb29","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.2005.05343.x"},{"key":"atypb30","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-410x.1998.00501.x"},{"key":"atypb31","doi-asserted-by":"publisher","DOI":"10.1016\/j.urology.2005.01.029"},{"key":"atypb32","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.08.036"}],"container-title":["Journal of Cardiovascular Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248408325404","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1074248408325404","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:38:29Z","timestamp":1777394309000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1074248408325404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,8,5]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,12]]}},"alternative-id":["10.1177\/1074248408325404"],"URL":"https:\/\/doi.org\/10.1177\/1074248408325404","relation":{},"ISSN":["1074-2484","1940-4034"],"issn-type":[{"value":"1074-2484","type":"print"},{"value":"1940-4034","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,8,5]]}}}